Xofigo (radium-223-dichloride) - Important Safety Information from Bayer AG as approved by the HPRA (December 2017)

Notice type: 3rd Party Publications

Date: 13/12/2017

Important Safety Information communication from Bayer AG on Xofigo (radium-223-dichloride): Increased risk of death and fractures in a randomized clinical trial with Xofigo used in combination with abiraterone acetate and prednisolone/prednisone.

Important Safety Information - Xofigo (radium-223-dichloride)